<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The human ETS family gene TEL2/ETV7 is highly homologous to TEL1/ETV6, a frequent target of chromosome translocations in human <z:hpo ids='HP_0001909'>leukemia</z:hpo> and specific <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Here we report that TEL2 augments the proliferation and survival of <z:mpath ids='MPATH_458'>normal</z:mpath> mouse B cells and dramatically accelerates <z:hpo ids='HP_0002665'>lymphoma</z:hpo> development in Emu-Myc transgenic mice </plain></SENT>
<SENT sid="2" pm="."><plain>Nonetheless, inactivation of the p53 pathway was a hallmark of <z:hpo ids='HP_0000001'>all</z:hpo> TEL2/Emu-Myc <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, indicating that TEL2 expression alone is insufficient to bypass this apoptotic checkpoint </plain></SENT>
<SENT sid="3" pm="."><plain>Although TEL2 is infrequently up-regulated in human <z:hpo ids='HP_0003745'>sporadic</z:hpo> Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, analysis of pediatric B-cell <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) samples showed increased coexpression of TEL2 and MYC and/or MYCN in over one-third of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, TEL2 and MYC also appear to cooperate in provoking a cadre of human B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>